Business
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a public offering price per share of $260.00. The gross proceeds from the offering are expecte
About this update from Praxis Precision Medicines, Inc.
[{"type":"image","alt":"Praxis Precision Medicines, Inc.","displaySize":"","headline":null,"caption":"Praxis Precision Medicines, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/605fef7bcd4287efde06f3c1abced879"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gfuDyxXigQjbpaazoPvi_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/605fef7bcd4287efde06f3c1abced879","width":300,"height":117}},"lazy":false},{"type":"text","content":"BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a public offering price per share of $260.00. The gross proceeds from the offering are expected to be approximately $575 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares in the offering are being offered by Praxis. In addition, Praxis has granted the underwriters a 30-day option to purchase up to 331,800 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 8, 2026, subject to market conditions and the satisfaction of customary closing conditions.","length":1044,"tagName":"p"},{"type":"text","content":"Piper Sandler, TD Cowen, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering. LifeSci Capital, Baird and Oppenheimer & Co. are acting as lead managers for the offering. H.C. Wainwright & Co. and Needham & Company are acting as co-managers for the offering.","length":319,"tagName":"p"},{"type":"text","content":"The offering is being made pursuant to a shelf registration statement on Form S-3ASR, including a base prospectus, that was filed by Praxis with the Securities and Exchange Commission (SEC) and automatically became effective upon filing on December 23, 2024. A preliminary prospectus supplement related to the offering was filed with the ...